Capricor Therapeutics
CAPR
108 hedge funds and large institutions have $239M invested in Capricor Therapeutics in 2024 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 35 increasing their positions, 15 reducing their positions, and 17 closing their positions.
200% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 17
133% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 15
88% more capital invested
Capital invested by funds: $127M → $239M (+$112M)
44% more funds holding
Funds holding: 75 → 108 (+33)
25% more call options, than puts
Call options by funds: $33.1M | Put options by funds: $26.6M
12.39% more ownership
Funds ownership: 25.72% → 38.11% (+12%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$39.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$29.7M |
| 3 |
BlackRock
New York
|
+$21.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.3M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$5.26M |
| 2 |
SCM
Superstring Capital Management
New York
|
-$4.94M |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$4.03M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.81M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.72M |
CAPR Hedge Fund Activity: Q4 2024 in Review
108 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q4 2024, worth a combined $239M — up 88% from $127M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new CAPR positions and 17 closed out — a net gain of 34 holders — while 35 added to existing stakes and 15 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $39.4M. The largest seller was Ikarian Capital, exiting entirely with an estimated $5.26M sold.
- 108 institutional investors held Capricor Therapeutics (CAPR) as of Q4 2024, up from 75 in Q3 2024.
- Funds reported $239M of Capricor Therapeutics stock for Q4 2024, up 88% quarter-over-quarter.
- 51 funds opened new Capricor Therapeutics positions in Q4 2024 and 17 closed out, a net change of +34 holders.
- The largest Capricor Therapeutics buyer in Q4 2024 was Farallon Capital Management, an estimated $39.4M added.
- The largest Capricor Therapeutics seller in Q4 2024 was Ikarian Capital, an estimated $5.26M sold.
Based on aggregated 13F filings for Q4 2024.